Copyright
©The Author(s) 2024.
World J Orthop. Aug 18, 2024; 15(8): 704-712
Published online Aug 18, 2024. doi: 10.5312/wjo.v15.i8.704
Published online Aug 18, 2024. doi: 10.5312/wjo.v15.i8.704
MSCs | PRP | HA |
(1) SC therapy utilizes various types of stem cells, such as those derived from adipose tissue, bone marrow, and the umbilical cord | (1) PRP contains elevated platelet concentrations and is used for tissue healing and regeneration, especially in conditions like OA | (1) Various HA derivatives are used for knee OA management, such as Hylan polymers, sodium hyaluronate and hyaluronan |
(2) AD-MSC intra-articular injections showed significant clinical and structural knee joint improvement over 6 and 12 mo, respectively | (2) In a laboratory study, PRP and high molecular weight HA were compared in their effects on gene expression and secretion of inflammatory mediators from OA cartilage and synoviocytes | (2) Hylan G-F20, a cross-linked HA product, has demonstrated effectiveness in relieving pain and improving function in knee OA, as well as delaying the need for total knee replacement |
(3) UC-MSC intra-articular injections showed significant clinical improvement over 12 mo with multiple injections, however, no structural improvement was observed | (3) PRP injections were found effective even in late-stage knee OA, enhancing pain relief and daily life activities | (3) Sodium hyaluronate, such as Supartz, has demonstrated significant pain reduction and improved function in mild to moderate symptomatic knee OA |
(4) BM-MSC intra-articular injections did not show significant clinical or structural improvement | (4) Optimal dosage of PRP with 10 billion platelets showed significant improvements in WOMAC and IKDC scores, along with decreased inflammatory markers like IL-6 and TNF-α | (4) The clinical benefits of hyaluronan injections compared to placebo remain inconclusive, suggesting the need for head-to-head comparisons with other HA preparations |
(5) Intra-articular injection of MSCs for OA is a safe treatment that showed no major adverse events | (5) PRP intra-articular injection has promising results for moderate to severe OA symptoms enhancement, regardless of leukocyte richness | (5) Current guidelines regarding viscosupplementation for knee OA are inconclusive and may evolve with emerging data supporting HA injections |
(6) Intraosseous injections of PRP did not provide additional benefits in OA knee treatment compared to intra-articular injections alone | (6) Safety assessments indicate slightly higher local adverse effects with intra-articular HA injections compared to placebo, but fewer systemic side effects than oral NSAIDs or acetaminophen | |
(7) Viscosupplementation may offer symptom relief but does not reverse the arthritic process or promote cartilage regeneration, emphasizing the need for ongoing research into its efficacy and long-term effects |
- Citation: Soufan S, Al Khoury J, Hamdan Z, Rida MA. Intra-articular interventions in osteoarthritis: Navigating the landscape of hyaluronic acid, mesenchymal stem cells, and platelet-rich plasma. World J Orthop 2024; 15(8): 704-712
- URL: https://www.wjgnet.com/2218-5836/full/v15/i8/704.htm
- DOI: https://dx.doi.org/10.5312/wjo.v15.i8.704